{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:40:57Z","timestamp":1792633257177,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:00:00Z","timestamp":1495497600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00415-017-8509-9","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T03:18:24Z","timestamp":1495509504000},"page":"1155-1164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases"],"prefix":"10.1007","volume":"264","author":[{"given":"Robbert-Jan","family":"Gieselbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie H.","family":"Muller-Hansma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn T.","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein S.","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob W.","family":"van Oosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis J.","family":"Nieuwkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank E.","family":"Coenjaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike P.","family":"Wattjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Murk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"8509_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fimmu.2015.00159","volume":"6","author":"MC Monaco","year":"2015","unstructured":"Monaco MC, Major EO (2015) Immune system involvement in the pathogenesis of JC virus induced PML: what is learned from studies of patients with underlying diseases and therapies as risk factors. Front Immunol 6:159. doi:\n                        10.3389\/fimmu.2015.00159","journal-title":"Front Immunol"},{"key":"8509_CR2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS Tan","year":"2010","unstructured":"Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9:425\u2013437","journal-title":"Lancet Neurol"},{"issue":"8","key":"8509_CR3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/apm.12128","volume":"121","author":"HH Hirsch","year":"2013","unstructured":"Hirsch HH, Kardas P, Kranz D, Leboeuf C (2013) The human JC polyomavirus (JCPyV): virological background and clinical implications. APMIS 121(8):685\u2013727","journal-title":"APMIS"},{"issue":"10","key":"8509_CR4","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1007\/s00415-016-8217-x","volume":"263","author":"RP Maas","year":"2016","unstructured":"Maas RP, Muller-Hansma AH, Esselink RA, Murk JL, Warnke C, Killestein J et al (2016) Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. J Neurol 263(10):2004\u20132021. doi:\n                        10.1007\/s00415-016-8217-x","journal-title":"J Neurol"},{"issue":"15","key":"8509_CR5","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ et al (2013) PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology 80(15):1430\u20131438","journal-title":"Neurology"},{"issue":"17","key":"8509_CR6","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMc1211805","volume":"368","author":"U Ermis","year":"2013","unstructured":"Ermis U, Weis J, Schulz JB (2013) PML in a patient treated with fumaric acid. N Engl J Med 368(17):1657\u20131658. doi:\n                        10.1056\/NEJMc1211805","journal-title":"N Engl J Med"},{"issue":"17","key":"8509_CR7","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJMc1215357","volume":"368","author":"BW Oosten Van","year":"2013","unstructured":"Van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP (2013) PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 368(17):1658\u20131659","journal-title":"N Engl J Med"},{"issue":"17","key":"8509_CR8","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMc1300283","volume":"368","author":"MT Sweetser","year":"2013","unstructured":"Sweetser MT, Dawson KT, Bozic C (2013) Manufacturer\u2019s response to case reports of PML. N Engl J Med 368(17):1659\u20131661. doi:\n                        10.1056\/NEJMc1300283","journal-title":"N Engl J Med"},{"issue":"11","key":"8509_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMc1307680#SA2","volume":"369","author":"M Buttmann","year":"2013","unstructured":"Buttmann M, Stoll G (2013) Case reports of PML in patients treated for psoriasis. N Engl J Med 369(11):1081. doi:\n                        10.1056\/NEJMc1307680#SA2","journal-title":"N Engl J Med"},{"issue":"5","key":"8509_CR10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00415-014-7311-1","volume":"261","author":"M Stoppe","year":"2014","unstructured":"Stoppe M, Thoma E, Liebert UG, Major EO, Hoffmann KT, Classen J et al (2014) Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis. J Neurol 261(5):1021\u20131024","journal-title":"J Neurol"},{"key":"8509_CR11","unstructured":"US Food & Drug Administration (2013) FDA approves new multiple sclerosis treatment: Tecfidera. \n                        https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm345528.htm"},{"key":"8509_CR12","unstructured":"European Medicines Agency (2014) Tecfidera: EPAR\u2014Public assessment report. \n                        http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002601\/WC500162070.pdf"},{"issue":"15","key":"8509_CR13","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1056\/NEJMc1415408","volume":"372","author":"T Rosenkranz","year":"2015","unstructured":"Rosenkranz T, Novas M, Terborg C (2015) PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 372(15):1476\u20131478. doi:\n                        10.1056\/NEJMc1415408","journal-title":"N Engl J Med"},{"key":"8509_CR14","unstructured":"Hughes S (2015) Fourth PML case with Tecfidera in MS calls for vigilance. Medscape. \n                        http:\/\/www.medscape.com\/viewarticle\/856148#vp_2\n                        \n                    . Accessed 21 February 2017"},{"issue":"4","key":"8509_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1586\/14737175.2015.1025755","volume":"15","author":"D Dubey","year":"2015","unstructured":"Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T et al (2015) Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Rev Neurother 15(4):339\u2013346. doi:\n                        10.1586\/14737175.2015.1025755","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"8509_CR16","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1212\/nxi.0000000000000076","volume":"2","author":"CM Spencer","year":"2015","unstructured":"Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS (2015) Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2(3):e76. doi:\n                        10.1212\/nxi.0000000000000076","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"8509_CR17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1177\/1352458515608961","volume":"22","author":"EE Longbrake","year":"2016","unstructured":"Longbrake EE, Ramsbottom MJ, Cantoni C, Ghezzi L, Cross AH, Piccio L (2016) Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Mult Scler 22(8):1061\u20131070. doi:\n                        10.1177\/1352458515608961","journal-title":"Mult Scler"},{"issue":"10","key":"8509_CR18","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/acn3.251","volume":"2","author":"Y Kihara","year":"2015","unstructured":"Kihara Y, Groves A, Rivera RR, Chun J (2015) Dimethyl fumarate inhibits integrin alpha4 expression in multiple sclerosis models. Ann Clin Transl Neurol 2(10):978\u2013983. doi:\n                        10.1002\/acn3.251","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"8509_CR19","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087\u20131097. doi:\n                        10.1056\/NEJMoa1206328","journal-title":"N Engl J Med"},{"issue":"12","key":"8509_CR20","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098\u20131107. doi:\n                        10.1056\/NEJMoa1114287","journal-title":"N Engl J Med"},{"issue":"15","key":"8509_CR21","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1517\/14656566.2013.826190","volume":"14","author":"E Havrdova","year":"2013","unstructured":"Havrdova E, Hutchinson M, Kurukulasuriya NC, Raghupathi K, Sweetser MT, Dawson KT et al (2013) Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97. Expert Opin Pharmacother 14(15):2145\u20132156. doi:\n                        10.1517\/14656566.2013.826190","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"8509_CR22","doi-asserted-by":"publisher","first-page":"e0120254","DOI":"10.1371\/journal.pone.0120254","volume":"10","author":"MS Brennan","year":"2015","unstructured":"Brennan MS, Matos MF, Li B, Hronowski X, Gao B, Juhasz P et al (2015) Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro. PLoS One 10(3):e0120254. doi:\n                        10.1371\/journal.pone.0120254","journal-title":"PLoS One"},{"key":"8509_CR23","unstructured":"Lareb (2016) Netherlands Pharmacovigilance Centre Lareb Databse. \n                        http:\/\/www.lareb.nl\n                        \n                    . Accessed 6 December 2016"},{"key":"8509_CR24","unstructured":"Eudravigilance (2016) Eudravigilance Database. \n                        http:\/\/bi.eudra.org\n                        \n                    . Accessed 6 December 2016"},{"issue":"15","key":"8509_CR25","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMc1413724","volume":"372","author":"DJ Nieuwkamp","year":"2015","unstructured":"Nieuwkamp DJ, Murk JL, van Oosten BW, Cremers CH, Killestein J, Viveen MC et al (2015) PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med 372(15):1474\u20131476. doi:\n                        10.1056\/NEJMc1413724","journal-title":"N Engl J Med"},{"issue":"4","key":"8509_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/ana.24471","volume":"78","author":"T Bartsch","year":"2015","unstructured":"Bartsch T, Rempe T, Wrede A, Leypoldt F, Bruck W, Adams O et al (2015) Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann Neurol 78(4):501\u2013514. doi:\n                        10.1002\/ana.24471","journal-title":"Ann Neurol"},{"key":"8509_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12883-015-0363-8","volume":"15","author":"N Dammeier","year":"2015","unstructured":"Dammeier N, Schubert V, Hauser TK, Bornemann A, Bischof F (2015) Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate. BMC Neurol 15:108. doi:\n                        10.1186\/s12883-015-0363-8","journal-title":"BMC Neurol"},{"issue":"3","key":"8509_CR28","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1212\/nxi.0000000000000085","volume":"2","author":"R Hoepner","year":"2015","unstructured":"Hoepner R, Faissner S, Klasing A, Schneider R, Metz I, Bellenberg B et al (2015) Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis. Neurol Neuroimmunol Neuroinflamm 2(3):e85. doi:\n                        10.1212\/nxi.0000000000000085","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"8509_CR29","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1212\/nxi.0000000000000177","volume":"2","author":"E Dubois","year":"2015","unstructured":"Dubois E, Ruschil C, Bischof F (2015) Low frequencies of central memory CD4 T cells in progressive multifocal leukoencephalopathy. Neurol Neuroimmunol Neuroinflamm 2(6):e177. doi:\n                        10.1212\/nxi.0000000000000177","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"8509_CR30","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1212\/wnl.0000000000002900","volume":"87","author":"K Lehmann-Horn","year":"2016","unstructured":"Lehmann-Horn K, Penkert H, Grein P, Leppmeier U, Teuber-Hanselmann S, Hemmer B et al (2016) PML during dimethyl fumarate treatment of multiple sclerosis: how does lymphopenia matter? Neurology 87(4):440\u2013441. doi:\n                        10.1212\/wnl.0000000000002900","journal-title":"Neurology"},{"issue":"5","key":"8509_CR31","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1212\/nxi.0000000000000274","volume":"3","author":"M Baharnoori","year":"2016","unstructured":"Baharnoori M, Lyons J, Dastagir A, Koralnik I, Stankiewicz JM (2016) Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 3(5):e274. doi:\n                        10.1212\/nxi.0000000000000274","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"16","key":"8509_CR32","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1212\/WNL.0000000000002586","volume":"86","author":"J Hodel","year":"2016","unstructured":"Hodel J, Darchis C, Outteryck O, Verclytte S, Deramecourt V, Lacour A et al (2016) Punctate pattern: a promising imaging marker for the diagnosis of natalizumab-associated PML. Neurology 86(16):1516\u20131523","journal-title":"Neurology"},{"issue":"10","key":"8509_CR33","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/jnnp-2016-313772","volume":"87","author":"MT Wijburg","year":"2016","unstructured":"Wijburg MT, Witte BI, Vennegoor A, Roosendaal SD, Sanchez E, Liu Y et al (2016) MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. J Neurol Neurosurg Psychiatry 87(10):1138\u20131145. doi:\n                        10.1136\/jnnp-2016-313772","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"8509_CR34","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/jnnp-2015-311411","volume":"87","author":"MP Wattjes","year":"2015","unstructured":"Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, de Vos M, Richert ND et al (2015) MRI characteristics of early PML\u2013IRIS after natalizumab treatment in patients with MS. J Neurol Neurosurg Psychiatry 87(8):879\u2013884. doi:\n                        10.1136\/jnnp-2015-311411","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"8509_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10096-013-1941-6","volume":"33","author":"JL Casado","year":"2014","unstructured":"Casado JL, Corral I, Garcia J, Martinez-San Millan J, Navas E, Moreno A et al (2014) Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV\/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis 33(2):179\u2013187. doi:\n                        10.1007\/s10096-013-1941-6","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"14","key":"8509_CR36","doi-asserted-by":"publisher","first-page":"7256","DOI":"10.1128\/jvi.02506-10","volume":"85","author":"S Gheuens","year":"2011","unstructured":"Gheuens S, Bord E, Kesari S, Simpson DM, Gandhi RT, Clifford DB et al (2011) Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 85(14):7256\u20137263. doi:\n                        10.1128\/jvi.02506-10","journal-title":"J Virol"},{"issue":"4","key":"8509_CR37","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","volume":"9","author":"DB Clifford","year":"2010","unstructured":"Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9(4):438\u2013446. doi:\n                        10.1016\/S1474-4422(10)70028-4","journal-title":"Lancet Neurol"},{"key":"8509_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/2055217315596994","author":"EE Longbrake","year":"2015","unstructured":"Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH (2015) Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J Exp Transl Clin. doi:\n                        10.1177\/2055217315596994","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"10","key":"8509_CR39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrneurol.2015.157","volume":"11","author":"MP Wattjes","year":"2015","unstructured":"Wattjes MP, Rovira A, Miller D, Yousry TA, Sormani MP, De Stefano N et al (2015) Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis\u2014establishing disease prognosis and monitoring patients. Nat Rev Neurol 11(10):597\u2013606","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"8509_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/jnnp-2015-311100","volume":"87","author":"C McGuigan","year":"2016","unstructured":"McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P et al (2016) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 87(2):117\u2013125. doi:\n                        10.1136\/jnnp-2015-311100","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"8509_CR41","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/acn3.114","volume":"1","author":"T Dong-Si","year":"2014","unstructured":"Dong-Si T, Richman S, Wattjes MP, Wenten M, Gheuens S, Philip J et al (2014) Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol 1(10):755\u2013764. doi:\n                        10.1002\/acn3.114","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"8509_CR42","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1136\/jnnp-2014-308630","volume":"86","author":"MP Wattjes","year":"2015","unstructured":"Wattjes MP, Vennegoor A, Steenwijk MD, de Vos M, Killestein J, van Oosten BW et al (2015) MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatry 86(7):793\u2013798. doi:\n                        10.1136\/jnnp-2014-308630","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"8509_CR43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00415-014-7530-5","volume":"262","author":"MT Wijburg","year":"2015","unstructured":"Wijburg MT, van Oosten BW, Murk J-L, Karimi O, Killestein J, Wattjes MP (2015) Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature. J Neurol 262(1):65\u201373. doi:\n                        10.1007\/s00415-014-7530-5","journal-title":"J Neurol"},{"issue":"4","key":"8509_CR44","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00415-015-8001-3","volume":"263","author":"MT Wijburg","year":"2016","unstructured":"Wijburg MT, Siepman D, van Eijk JJ, Killestein J, Wattjes MP (2016) Concomitant granule cell neuronopathy in patients with natalizumab-associated PML. J Neurol 263(4):649\u2013656. doi:\n                        10.1007\/s00415-015-8001-3","journal-title":"J Neurol"},{"issue":"2","key":"8509_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nrrheum.2014.167","volume":"11","author":"LH Calabrese","year":"2015","unstructured":"Calabrese LH, Molloy E, Berger J (2015) Sorting out the risks in progressive multifocal leukoencephalopathy. Nat Rev Rheumatol 11(2):119\u2013123. doi:\n                        10.1038\/nrrheum.2014.167","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"8509_CR46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2133.2003.05433.x","volume":"149","author":"JJ Hoefnagel","year":"2003","unstructured":"Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN (2003) Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 149(2):363\u2013369","journal-title":"Br J Dermatol"},{"issue":"7","key":"8509_CR47","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1610-0387.2009.07120.x","volume":"7","author":"K Reich","year":"2009","unstructured":"Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T (2009) Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis\u2014a retrospective study (FUTURE). J Dtsch Dermatol Ges 7(7):603\u2013611. doi:\n                        10.1111\/j.1610-0387.2009.07120.x","journal-title":"J Dtsch Dermatol Ges"},{"issue":"9","key":"8509_CR48","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1177\/1352458515615225","volume":"22","author":"MP Wattjes","year":"2015","unstructured":"Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, Roosendaal SD, Sanchez E et al (2015) Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients. Mult Scler 22(9):1174\u20131183. doi:\n                        10.1177\/1352458515615225","journal-title":"Mult Scler"},{"key":"8509_CR49","unstructured":"European Medicines Agency (2015) Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera. \n                        http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2015\/10\/news_detail_002423.jsp&mid=WC0b01ac058004d5c1"}],"updated-by":[{"DOI":"10.1007\/s00415-017-8557-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T00:00:00Z","timestamp":1500076800000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-017-8509-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-017-8509-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-017-8509-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T07:05:00Z","timestamp":1502348700000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-017-8509-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["8509"],"URL":"https:\/\/doi.org\/10.1007\/s00415-017-8509-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00415-017-8557-1","asserted-by":"object"}]},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,23]]}}}